Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: Results from the Prostate Cancer Prevention Trial

Alan R. Kristal, Jeannette M. Schenk, Yoon Ju Song, Kathryn B. Arnold, Marian L. Neuhouser, Phyllis J. Goodman, Daniel W. Lin, Frank Z. Stanczyk, Ian M. Thompson

Research output: Contribution to journalArticlepeer-review

53 Scopus citations

Abstract

The authors conducted a nested case-control study of serum steroid concentrations and risk of benign prostatic hyperplasia (BPH), using data from the placebo arm of the Prostate Cancer Prevention Trial (1993-2003). Incident BPH over 7 years (n = 708) was defined as receipt of treatment, a report of 2 International Prostate Symptom Score (IPSS) values greater than 14, or 2 increases of 5 or more from baseline IPSS values with at least 1 value greater than or equal to 12. Controls (n = 709) were selected from men who reported no BPH treatment or any IPSS greater than 7. Baseline serum was analyzed for testosterone, estradiol, estrone, 5α-androstane-3α, 17β-diol-glucuronide, and sex hormone-binding globulin. Covariate-adjusted odds ratios contrasting the highest quartiles with the lowest quartiles of testosterone, estradiol, and testosterone:17β-diol-glucuronide ratio were 0.64 (95% confidence interval (CI): 0.43, 0.95; Ptrend = 0.04), 0.72 (95% CI: 0.53, 0.98; Ptrend = 0.09), and 0.64 (95% CI: 0.46, 0.89; Ptrend = 0.004), respectively. Findings did not differ by age, body mass index, time to BPH endpoint, or type of BPH endpoint. High testosterone levels, estradiol levels, and testosterone:17β-diol-glucuronide ratio are associated with reduced BPH risk, which may reflect decreased activity of 5-α-reductase. Genetic or environmental factors that affect the activity of 5-α-reductase may be important in the development of symptomatic BPH.

Original languageEnglish (US)
Pages (from-to)1416-1424
Number of pages9
JournalAmerican journal of epidemiology
Volume168
Issue number12
DOIs
StatePublished - Dec 2008

Keywords

  • Gonadal steroid hormones
  • Prostatic hyperplasia

ASJC Scopus subject areas

  • Epidemiology

Fingerprint Dive into the research topics of 'Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: Results from the Prostate Cancer Prevention Trial'. Together they form a unique fingerprint.

Cite this